Blood pressure increases and other safety and medication compliance in overactive bladder patients treated with Selebeta<sup>®</sup> PR tablets: A noninterventional, multicenter, retrospective observational study. [PDF]
Investig Clin UrolLee JH, Kim A, Shim JS, Ko KJ.
europepmc +1 more source
Side effects of medical therapy for non-neurogenic lower urinary tract symptoms in children: a UK-based single centre retrospective case-note review. [PDF]
BMJ Paediatr OpenWong J, Corbett HJ.
europepmc +1 more source
An updated meta-analysis of head-to-head trials comparing the efficacy, safety, and adherence of mirabegron and vibegron in overactive bladder. [PDF]
Medicine (Baltimore)Bai WZ, Zhou SY, Mou YY, Peng L, Li LL.
europepmc +1 more source
Mirabegron administration for the prevention of ureteral injuries during ureteral access sheath insertion. [PDF]
World J UrolErmiş O +6 more
europepmc +1 more source
Effects of Ranolazine on Vascular Adrenergic Receptors in Rabbit Aorta. [PDF]
Int J Med SciJorda A +5 more
europepmc +1 more source
Impact of Elexacaftor-Tezacaftor-Ivacaftor on Quality of Life in Children With Cystic Fibrosis. [PDF]
Pediatr PulmonolKümmerli S +6 more
europepmc +1 more source
Distinct Conformations of Mirabegron Determined by MicroED. [PDF]
Adv Sci (Weinh), 2023 Lin J, Unge J, Gonen T.
europepmc +1 more source
Clinical CYP2D6-Mediated Pharmacokinetic Drug-Drug Interactions of DA-8010 with Paroxetine or Mirabegron in Healthy Korean Participants. [PDF]
Drug Des Devel TherRyu H, Cho JY, Lee DY, Lee S.
europepmc +1 more source